Details

Autor(en) / Beteiligte

• Katz, Moshe
• Freimark, Dov
• Raichlin, Eugenia
• Har‐Zahav, Yedael
• Arad, Michael
• Kassif, Yigal
• Peled, Amir
• Asher, Elad
• Elian, Dan
• Kogan, Alexander
• Shlomo, Nir
• Ofek, Efrat
• Lavee, Jacob
• Goldenberg, Ilan
• Peled, Yael

Titel

Risk of early, intermediate, and late rejection following heart transplantation: Trends over the past 25 years and relation to changes in medical management. Tertiary center experience: The Sheba Heart Transplantation Registry

Ist Teil von

• Clinical transplantation, 2017-10, Vol.31 (10), p.n/a

Ort / Verlag

Denmark

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Aim To explore the trends in the risk for rejection following heart transplantation (HT) over the past 25 years, and their relation to changes in medical management. Methods The study population comprised 216 HT patients. Rejection periods were defined as follows: 0‐3 months (early), 3‐12 months (intermediate), and 12+ months (late). HT era was dichotomized as follows: 1991‐1999 (remote era) and 2000‐2016 (recent era). Medication combination was categorized as newer (TAC, MMF, and everolimus) vs older therapies (AZA, CSA). Results Multivariate analysis showed that patients who underwent HT during the recent era experienced a significant reduction in the risk for major rejection. These findings were consistent for early (OR = 0.44 [95% CI 0.22‐0.88]), intermediate (OR = 0.02 [95% CI 0.003‐0.11]), and late rejections (OR = 0.18 [95% CI 0.05‐0.52]). Using the year of HT as a continuous measure showed that each 1‐year increment was independently associated with a significant reduction in the risk for early, intermediate, and late rejections (5%, 21%, 18%, respectively). In contrast, the risk reduction associated with newer types of immunosuppressive therapies was not statistically significant after adjustment for the treatment period. Conclusions Major rejection rates following HT have significantly declined over the past 2 decades even after adjustment for changes in immunosuppressive therapies, suggesting that other factors may also play a role in the improved outcomes of HT recipients.